Key Takeaways
- Solis Agrosciences acquired Ferris Genomics’ sequencing and bioinformatics platform to offer comprehensive genomics services.
- The acquisition includes capabilities like whole-genome sequencing, skim sequencing, and imputation for breeding programs.
- Key Ferris employees joined Solis, ensuring a seamless transition of operations.
- The expanded services strengthen Solis’ position in delivering high-quality AgTech research solutions.
Solis Agrosciences (Company Profile) has announced the acquisition of Ferris Genomics’ sequencing and bioinformatics platform. This strategic move enables Solis to provide end-to-end genomics solutions, enhancing its offerings for plant and animal research and breeding programs.
Enhanced Genomics Services for Agriculture
The Ferris Genomics platform brings advanced tools to Solis’ portfolio, including:
- Whole-Genome Sequencing
- Skim Sequencing with Imputation
- Customized Genomics-Driven Breeding Program Development
Ferris, founded by genomics experts, has established a reputation for delivering high-quality data to customers across diverse agricultural applications, including row crops, specialty crops, and livestock.
Strategic Fit and Operational Synergy
“Ferris Genomics is an attractive asset that offers marketplace and operational synergy, allowing Solis to deliver more comprehensive solutions and to reach new customers,” said Charlie Bolten, co-founder and CEO of Solis Agrosciences. “We anticipate that the acquisition of this platform and its experienced team will immediately contribute to Solis’ bottom line.”
To ensure continuity, key Ferris team members have joined Solis, and operations at the Ferris laboratories in the Helix Center—located within the same building as Solis’ headquarters—are now fully integrated.
Driving Innovation in Agricultural Research
Solis’ expanded capabilities include advanced sequencing technologies that offer actionable insights for breeders. Susan Martino-Catt, PhD, COO of Solis Agrosciences, explained, “Whole-genome skim sequencing and hybrid-capture approaches with imputation have reached a price point where the technology can be broadly deployed in agriculture to drive phenotypic gain while maintaining genetic diversity in breeding programs.”
These technologies align with Solis’ existing platforms in plant transformation and genome editing, providing customers with comprehensive solutions to enhance phenotypic traits.
Backed by Leading Investors
Solis has demonstrated significant growth since its founding in 2022, with a robust investor base that includes Hermann Companies, Saloniki Investments, BioGenerator Ventures, QRM Capital, and others.
Robert Hermann, Jr., chairman and CEO of Hermann Companies, expressed optimism about Solis’ trajectory: “We look forward to future growth and additional opportunities to add capability that builds shareholder value.”